Prostatic Neoplasms

"Prostatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the PROSTATE.

Descriptor ID	D011471
MeSH Number(s)	C04.588.945.440.770 C12.294.260.750 C12.294.565.625 C12.758.409.750
Concept/Terms	Prostatic Neoplasms Prostatic Neoplasms Prostate Neoplasms Neoplasms, Prostate Neoplasm, Prostate Prostate Neoplasm Neoplasms, Prostatic Neoplasm, Prostatic Prostatic Neoplasm Prostate Cancer Prostate Cancer Cancer, Prostate Cancers, Prostate Prostate Cancers Cancer of the Prostate Prostatic Cancer Cancer, Prostatic Cancers, Prostatic Prostatic Cancers Cancer of Prostate

Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Genital Neoplasms, Male [C04.588.945.440]
Prostatic Neoplasms [C04.588.945.440.770]
Male Urogenital Diseases [C12]
Genital Diseases, Male [C12.294]
Genital Neoplasms, Male [C12.294.260]
Prostatic Neoplasms [C12.294.260.750]
Prostatic Diseases [C12.294.565]
Prostatic Neoplasms [C12.294.565.625]
Urogenital Neoplasms [C12.758]
Genital Neoplasms, Male [C12.758.409]
Prostatic Neoplasms [C12.758.409.750]

Below are MeSH descriptors whose meaning is related to "Prostatic Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms".

Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Prostatic Neoplasms" by people in this website by year, and whether "Prostatic Neoplasms" was a major or minor topic of these publications.

Bar chart showing 692 publications over 31 distinct years, with a maximum of 67 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	4	0	4
1994	3	0	3
1995	2	1	3
1996	7	0	7
1997	7	2	9
1998	9	1	10
1999	13	1	14
2000	8	1	9
2001	7	1	8
2002	26	3	29
2003	45	4	49
2004	36	6	42
2005	33	4	37
2006	27	1	28
2007	43	5	48
2008	39	3	42
2009	49	6	55
2010	55	6	61
2011	64	3	67
2012	25	1	26
2013	21	2	23
2014	13	1	14
2015	14	2	16
2016	16	1	17
2017	17	3	20
2018	7	0	7
2019	3	0	3
2020	6	0	6
2021	11	0	11
2022	16	0	16
2023	8	0	8

Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles.

Oyer HM, Steck AR, Longen CG, Venkat S, Bayrak K, Munger EB, Fu D, Castagnino PA, Sanders CM, Tancler NA, Mai MT, Myers JP, Schiewer MJ, Chen N, Mostaghel EA, Kim FJ. Sigma1 Regulates Lipid Droplet-mediated Redox Homeostasis Required for Prostate Cancer Proliferation. Cancer Res Commun. 2023 10 30; 3(10):2195-2210.

View in: PubMed
Freedland SJ, Samjoo IA, Rosta E, Lansing A, Worthington E, Niyazov A, Nazari J, Arondekar B. The impact of race on survival in metastatic prostate cancer: a systematic literature review. Prostate Cancer Prostatic Dis. 2023 09; 26(3):461-474.

View in: PubMed
Gomaa S, Kelly WK, Mitchell E, Storozynsky E, Zeigler-Johnson C, Juon HS, Wen KY. Racial disparities in new-onset diabetes mellitus in prostate cancer patients on androgen deprivation therapy: a retrospective analysis of TriNetX data. World J Urol. 2023 Sep; 41(9):2351-2357.

View in: PubMed
Lazarovich A, Chandrasekar T, Basnet A, Bratslavsky G, Goldberg H. Does a prior cancer diagnosis impact PSA testing? Results from the National Health Interview Survey. Can J Urol. 2023 06; 30(3):11551-11557.

View in: PubMed
Pol M, Gao H, Zhang H, George OJ, Fox JM, Jia X. Dynamic modulation of matrix adhesiveness induces epithelial-to-mesenchymal transition in prostate cancer cells in 3D. Biomaterials. 2023 Aug; 299:122180.

View in: PubMed
Burnett AL, Nyame YA, Mitchell E. Disparities in prostate cancer. J Natl Med Assoc. 2023 May; 115(2S):S38-S45.

View in: PubMed
Akin O, Woo S, Oto A, Allen BC, Avery R, Barker SJ, Gerena M, Halpern DJ, Gettle LM, Rosenthal SA, Taneja SS, Turkbey B, Whitworth P, Nikolaidis P. ACR Appropriateness Criteria? Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023 05; 20(5S):S187-S210.

View in: PubMed
Ogunsanya ME, Sifat M, Bamidele OO, Ezenwankwo EF, Clifton S, Ton C, Knight JM, Odedina FT, Greer JA, Dwyer K, Kendzor DE. Mobile health (mHealth) interventions in prostate cancer survivorship: a scoping review. J Cancer Surviv. 2023 06; 17(3):557-568.

View in: PubMed
Awasthi S, Grass GD, Torres-Roca J, Johnstone PAS, Pow-Sang J, Dhillon J, Park J, Rounbehler RJ, Davicioni E, Hakansson A, Liu Y, Fink AK, DeRenzis A, Creed JH, Poch M, Li R, Manley B, Fernandez D, Naghavi A, Gage K, Lu-Yao G, Katsoulakis E, Burri RJ, Leone A, Ercole CE, Palmer JD, Vapiwala N, Deville C, Rebbeck TR, Dicker AP, Kelly W, Yamoah K. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease. J Natl Cancer Inst. 2022 12 08; 114(12):1656-1664.

View in: PubMed
Sayyid RK, Benton JZ, Reed WC, Woodruff P, Terris MK, Wallis CJD, Klaassen Z. Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis. World J Urol. 2023 Jan; 41(1):93-99.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement